Gemcitabine (G) followed by 2nd line Docetaxel (D) is feasible in advanced NSCLC: Results from a randomized phase II studyCh Manegold, L Pitz, Gisela Koschel,Katrin Schott, E Waletzko,D Hruska,W Dornoff,H Gosse,Ulrich GatzemeierLung Cancer(2000)引用 9|浏览6暂无评分关键词phase ii studyAI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要